Short Term Rating on Spark Therapeutics (ONCE)

Spark Therapeutics (ONCE) has an average broker rating of 2.14, which is interpreted as a Buy, as rated by 7 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Spark Therapeutics (ONCE) : Currently there are 7 street experts covering Spark Therapeutics (ONCE) stock. The most bullish and bearish price target for the stock is $94 and $29 respectively for the short term. The average price target of all the analysts comes to $57.14. The estimated standard deviation from the target is $24.45.

Company shares have received an average consensus rating of Hold for the current week


Spark Therapeutics (NASDAQ:ONCE): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $56.10 and $55.12 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $59.61. The buying momentum continued till the end and the stock did not give up its gains. It closed at $57.13, notching a gain of 4.88% for the day. The total traded volume was 1,172,252 . The stock had closed at $54.47 on the previous day.

Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. Sparks product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs, including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Companys product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *